Comparison of 5 Different Rat Models to Establish a Standard Animal Model for Research Into Interstitial Cystitis
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Purpose: We evaluated 5 different rat models using different agents in order to establish a standard animal model for interstitial cystitis (IC) in terms of the functional and pathologic characteristics of the bladder. Methods: Five IC models were generated in 8-week-old female Sprague-Dawley rats via transurethral instillation of 0.1M hydrogen chloride (HCl) or 3% acetic acid (AA), intraperitoneal injection of cyclophosphamide (CYP) or lipopolysaccharide (LPS), or subcutaneous injection of uroplakin II (UPK2). After generating the IC models, conscious cystometry was performed on days 3, 7, and 14. All rats were euthanized on day 14 and their bladders were obtained for histological and pro-inflammatory- related gene expression analysis. Results: In the cystometric analysis, all experimental groups showed significantly decreased intercontraction intervals compared with the control group on day 3, but only the LPS and UPK groups maintained significantly shorter intercontraction intervals than the control group on day 14. The histological analysis revealed that areas with severe urothelial erosion (HCl, AA, and UPK) and hyperplasia (CYP and LPS), particularly in the UPK-treated bladders, showed a markedly increased infiltration of toluidine blue-stained mast cells and increased tissue fibrosis. In addition, significantly elevated expression of interleukin- 1b, interleukin-6, myeloperoxidase, monocyte chemotactic protein 1, and Toll-like receptors 2 and 4 was observed in the UPK group compared to the other groups. Conclusions: Among the 5 different agents, the injection of UPK generated the most effective IC animal model, showing consequent urothelial barrier loss, inflammatory reaction, tissue fibrosis stimulation, and persistent hyperactive bladder.
Abstract
Purpose: We evaluated 5 different rat models using different agents in order to establish a standard animal model for interstitial cystitis (IC) in terms of the functional and pathologic characteristics of the bladder. Methods: Five IC models were generated in 8-week-old female Sprague-Dawley rats via transurethral instillation of 0.1M hydrogen chloride (HCl) or 3% acetic acid (AA), intraperitoneal injection of cyclophosphamide (CYP) or lipopolysaccharide (LPS), or subcutaneous injection of uroplakin II (UPK2). After generating the IC models, conscious cystometry was performed on days 3, 7, and 14. All rats were euthanized on day 14 and their bladders were obtained for histological and pro-inflammatory- related gene expression analysis. Results: In the cystometric analysis, all experimental groups showed significantly decreased intercontraction intervals compared with the control group on day 3, but only the LPS and UPK groups maintained significantly shorter intercontraction intervals than the control group on day 14. The histological analysis revealed that areas with severe urothelial erosion (HCl, AA, and UPK) and hyperplasia (CYP and LPS), particularly in the UPK-treated bladders, showed a markedly increased infiltration of toluidine blue-stained mast cells and increased tissue fibrosis. In addition, significantly elevated expression of interleukin- 1b, interleukin-6, myeloperoxidase, monocyte chemotactic protein 1, and Toll-like receptors 2 and 4 was observed in the UPK group compared to the other groups. Conclusions: Among the 5 different agents, the injection of UPK generated the most effective IC animal model, showing consequent urothelial barrier loss, inflammatory reaction, tissue fibrosis stimulation, and persistent hyperactive bladder.
참고문헌 (28)
- Bogart LM, "Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review", J Urol, 177, pp.450~456 (2007)
- Chancellor MB, "Treatment of interstitial cystitis", Urology, 63(3 Suppl 1), pp.85~92 (2004)
- Kim A, "Stem Cell Therapy for interstitial cystitis", bladder pain syndrome, 2016, pp.17, 1~
- Clemens JQ, "Prevalence of interstitial cystitis symptoms in a managed care population", J Urol, 174, pp.576~580 (2005)
- Sea J, "Paediatric painful bladder syndrome", interstitial cystitis : diagnosis and treatment, 2009, pp.69, 279~296
- Sand PK., "Proposed pathogenesis of painful bladder syndrome", interstitial cystitis, 2006, pp.51(3 Suppl), 234~240
- Adamowicz J, "Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials", Med Hypotheses, 82, pp.670~673 (2014)
- Song M, "mesenchymal stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway", Stem Cells Dev, 24, pp.1648~1657 (2015)
- Altuntas CZ, "Autoimmunity to uroplakin II causes cystitis in mice : a novel model of interstitial cystitis", Eur Urol, 61, pp.193~200 (2012)
- Birder LA, "Altered inducible nitric oxide synthase expression and nitric oxide production in the bladder of cats with feline interstitial cystitis", J Urol, 173, pp.625~629 (2005)
- Bon K, "Characterization of cyclophosphamide cystitis, a model of visceral and referred pain, in the mouse: species and strain differences", J Urol, 170, pp.1008~1012 (2003)
- Fraser MO, "A reliable, nondestructive animal model for interstitial cystitis: intravesical low-dose protamine sulfate combined with physiological concentrations of potassium chloride", Urology, 57(6 Suppl 1), pp.112~ (2001)
- Kirimoto T, "Beneficial effects of suplatast tosilate(IPD-1151T)in a rat cystitis model induced by intravesical hydrochloric acid", BJU Int, 100, pp.935~939 (2007)
- Tambaro S, "Evaluation of selective cannabinoid CB(1)and CB(2)receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis", Eur J Pharmacol, 729, pp.67~74 (2014)
- Westropp JL, "In vivo models of interstitial cystitis", J Urol, 167(2 Pt 1), pp.694~702 (2002)
- Golubeva AV, "The mouse cyclophosphamide model of bladder pain syndrome: tissue characterization, immune profiling, and relationship to metabotropic glutamate receptors", Physiol Rep, 2, pp.e00260~ (2014)
- Keay S, "A mouse model for interstitial cystitis", painful bladder syndrome based on APF inhibition of bladder epithelial repair : a pilot study, 2012, pp.12, 17~
- Bjorling DE, "Models of inflammation of the lower urinary tract", Neurourol Urodyn, 30, pp.673~682 (2011)
- Elgebaly SA, "Urinary neutrophil chemotactic factors in interstitial cystitis patients and a rabbit model of bladder inflammation", J Urol, 147, pp.1382~1387 (1992)
- Kato K, "Time-course of alterations of bladder function following acetone-induced cystitis", J Urol, 144, pp.1272~1276 (1990)
- McMahon SB, "A model for the study of visceral pain states : chronic inflammation of the chronic decerebrate rat urinary bladder by irritant chemicals", Pain, 28, pp.109~127 (1987)
- Sakata T, "Rat urinary bladder epithelial lesions induced by acrolein", J Environ Pathol Toxicol Oncol, 9, pp.159~169 (1989)
- Jasmin L, "CNS induced neurogenic cystitis is associated with bladder mast cell degranulation in the rat", J Urol, 164(3 Pt 1), pp.852~855 (2000)
- Izgi K, "Uroplakin peptide-specific autoimmunity initiates interstitial cystitis", painful bladder syndrome in mice, 2013, pp.8, e72067~
- Keay S, "Urine autoantibodies in interstitial cystitis", J Urol, 157, pp.1083~1087 (1997)
- Ochs RL, "Autoantibodies and interstitial cystitis", Clin Lab Med, 17, pp.571~579 (1997)
- van de Merwe JP, "Interstitial cystitis and systemic autoimmune diseases", Nat Clin Pract Urol, 4, pp.484~491 (2007)
- Lorenzo Gómez MF, "Physiopathologic relationship between interstitial cystitis and rheumatic, autoimmune, and chronic inflammatory diseases", Arch Esp Urol, 57, pp.25~34 (2004)